WO2009055596A3 - Methods of using genetic variants to diagnose and predict metabolic syndrome and associated traits - Google Patents

Methods of using genetic variants to diagnose and predict metabolic syndrome and associated traits Download PDF

Info

Publication number
WO2009055596A3
WO2009055596A3 PCT/US2008/080996 US2008080996W WO2009055596A3 WO 2009055596 A3 WO2009055596 A3 WO 2009055596A3 US 2008080996 W US2008080996 W US 2008080996W WO 2009055596 A3 WO2009055596 A3 WO 2009055596A3
Authority
WO
WIPO (PCT)
Prior art keywords
metabolic syndrome
locus
diagnose
methods
genetic variants
Prior art date
Application number
PCT/US2008/080996
Other languages
French (fr)
Other versions
WO2009055596A2 (en
Inventor
Jerome I. Rotter
Kent D. Taylor
Yi Der I. Chen
Mark O. Goodarzi
Xiuqing Guo
Janet Yu
Talin Haritunians
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Publication of WO2009055596A2 publication Critical patent/WO2009055596A2/en
Publication of WO2009055596A3 publication Critical patent/WO2009055596A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to method of diagnosing metabolic syndrome and associated traits. In one embodiment, the present invention provides a method of diagnosing susceptibility to metabolic syndrome and/or cardiovascular disease by determining the presence of a risk variant from the CMYA3 locus, NTN1 locus, TGFβ2 locus, SMAD3 locus and/or THSD7B locus in an individual.
PCT/US2008/080996 2007-10-23 2008-10-23 Methods of using genetic variants to diagnose and predict metabolic syndrome and associated traits WO2009055596A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98203607P 2007-10-23 2007-10-23
US60/982,036 2007-10-23
US2113508P 2008-01-15 2008-01-15
US61/021,135 2008-01-15

Publications (2)

Publication Number Publication Date
WO2009055596A2 WO2009055596A2 (en) 2009-04-30
WO2009055596A3 true WO2009055596A3 (en) 2009-12-30

Family

ID=40580390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/080996 WO2009055596A2 (en) 2007-10-23 2008-10-23 Methods of using genetic variants to diagnose and predict metabolic syndrome and associated traits

Country Status (1)

Country Link
WO (1) WO2009055596A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178294B2 (en) 2002-06-14 2012-05-15 Cedars-Sinai Medical Center Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes
DE102015222002A1 (en) 2014-11-07 2016-05-12 Aj Innuscreen Gmbh A method for the selective size fractionated separation and isolation of nucleic acid mixtures
US10731219B1 (en) 2019-09-19 2020-08-04 Dasman Diabetes Institute Method for preventing progression to metabolic syndrome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072170A1 (en) * 2000-05-30 2004-04-15 Bunk Daniela Beck Nee Novel target genes for diseases of the heart
US20040192583A1 (en) * 2002-12-19 2004-09-30 Satyanarayana Medicherla Treatment of obesity and associated conditions with TGF-beta inhibitors
US20060019896A1 (en) * 2004-07-14 2006-01-26 University Of Utah Research Foundation Netrin-related compositions and uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072170A1 (en) * 2000-05-30 2004-04-15 Bunk Daniela Beck Nee Novel target genes for diseases of the heart
US20040192583A1 (en) * 2002-12-19 2004-09-30 Satyanarayana Medicherla Treatment of obesity and associated conditions with TGF-beta inhibitors
US20060019896A1 (en) * 2004-07-14 2006-01-26 University Of Utah Research Foundation Netrin-related compositions and uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI [online] 7 September 2001 (2001-09-07), "Homo sapiens BAC clone RP11-681B22 from 2", retrieved from http://www.ncbi.nlm.nih.gov/nuccore/19071705 Database accession no. AC093684 *
LOPEZ-CAPAPE ET AL.: "Frequency of the metabolic syndrome in obese Spanish pediatric population", EUR J ENDOCRINOL, vol. 155, no. 2, August 2006 (2006-08-01), pages 313 - 309 *

Also Published As

Publication number Publication date
WO2009055596A2 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
NZ576061A (en) Biomarkers
WO2008015254A3 (en) Means and methods for assessing the risk of cardiac interventions based on gdf-15
WO2011135194A3 (en) Method for diagnosing risk of type 1 diabetes and for preventing onset of type 1 diabetes
WO2009052512A3 (en) Methods of using genetic variants to diagnose and predict inflammatory bowel disease
WO2008109773A3 (en) Chronic obstructive pulmonary disease susceptibility and related compositions and methods
IL191538A0 (en) Method for diagnosing, prognosing and treating glioma
WO2011031786A3 (en) Compositions and methods for diagnosing autism spectrum disorders
BRPI0710123A2 (en) Prediction of HETEROSIS AND OTHER TRAITS BY TRANSCRIPTOM ANALYSIS.
WO2008097277A3 (en) Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
WO2007061906A3 (en) Diagnostic and therapeutics for cardiovascular disorders
WO2012125872A3 (en) Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof
WO2009111595A9 (en) Diagnosing and monitoring depression disorders based on multiple biomarker panels
WO2011011426A3 (en) Methods for assessing disease risk
GB2481950B (en) Surface microstructure measurement method, surface microstructure measurement data analysis method and surface microstructure measurement system.
WO2010099342A3 (en) Methods of detecting lung cancer
WO2009152521A3 (en) Diagnosis of neurodegenerative disorders
BRPI0913112A2 (en) flowmeter and method.
WO2008152656A3 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
WO2009104974A3 (en) Biomarkers for acute coronary disorder
WO2008091948A3 (en) Galectin-3-binding, protein as a biomarker of cardiovascular disease
JP2010528620A5 (en)
WO2008065682A3 (en) Genetic susceptibility variants of type 2 diabetes mellitus
WO2013090857A8 (en) Identification of two novel biomarkers for niemann-pick disease type c
WO2009055596A3 (en) Methods of using genetic variants to diagnose and predict metabolic syndrome and associated traits
GB0816147D0 (en) Game system, detection program and detection method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08843004

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08843004

Country of ref document: EP

Kind code of ref document: A2